Post-cardiac transplantation gout: incidence of therapeutic complications

Anita E. Wluka, Peter F.J. Ryan, Ashley M. Miller, Meroula Richardson, Peter J. Bergin, Judith L. Page, Donald S. Esmore

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)


Objective: To study the clinical impact of gout treatment following cardiac transplantation.MethodsWe performed an audit of all cardiac transplant recipients of the Alfred Hospital before August 1998 who lived in Victoria. Results: We studied 225 patients (81% men), with a mean post-transplant follow-up of 50.8 months (SD 36). Forty-three (19%) had pre-transplant gout, 19 recurring post-transplantation. Twenty-three patients developed gout de novo.Of the 24 patients who received allopurinol, 6 developed pancytopenia and required hospitalization. Fourteen received a change in immunosuppression: in 5 patients following pancytopenia, and in 9 to enable safe use of allopurinol. Thirty-two patients received colchicine; 5 developed neuromyopathy. Impaired renal function, diuretic use, and hypertension were more common in this sub-group. Non-steroidal anti-inflammatory agents, used in 16 patients, caused serious complications in 1 patient (life-threatening peptic ulceration and hemorrhage, precipitating dialysis-dependent chronic renal failure). Conclusions: Cardiac transplant recipients, when treated for gout, are at high risk of therapeutic complications. Thus, gout treatment significantly affects care, health, and immunosuppression of these patients. Copyright (C) 2000 International Society for Heart and Lung Transplantation.

Original languageEnglish
Pages (from-to)951-956
Number of pages6
JournalThe Journal of Heart and Lung Transplantation
Issue number10
Publication statusPublished - 23 Oct 2000
Externally publishedYes

Cite this